Lomitapide

證據等級: L5

預測適應症: 10 個

Lomitapide: From Homozygous Familial Hypercholesterolemia to Macrothrombocytopenia with Mitral Valve Insufficiency

One-Sentence Summary

Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor already approved abroad for homozygous familial hypercholesterolemia (HoFH) — though this original indication is missing from the structured drug record and only surfaces indirectly in the evidence pack's literature. The TxGNN model's top-ranked new prediction is macrothrombocytopenia with mitral valve insufficiency, a rare inherited platelet disorder. This prediction is supported by zero clinical trials and zero publications — it is a pure model score with no mechanistic rationale.

Quick Overview

Item	Content
Original Indication	Not present in structured data (`original_indications` is empty). Homozygous Familial Hypercholesterolemia (HoFH) is inferable from the literature/trial evidence attached to a different ranked entry (see note below), but is not confirmed in the drug record.
Predicted New Indication	Macrothrombocytopenia with mitral valve insufficiency
TxGNN Prediction Score	99.92%
Evidence Level	L5 (model prediction only, no supporting studies)
Taiwan Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is officially flagged as a data gap (DG002) in this evidence pack. Based on information surfacing elsewhere in the pack, lomitapide is known to act as an MTP inhibitor, blocking hepatic and intestinal apoB-lipoprotein assembly to lower LDL-C/VLDL — the basis of its established use in severe hypercholesterolemia.

For the top-ranked predicted indication, macrothrombocytopenia with mitral valve insufficiency, the evidence pack's own rationale is explicit: "an extremely rare hereditary disorder with no known pathological link to MTP inhibition. This is purely a graph neural network prediction score, unsupported by any mechanism, trial, or literature." There is no plausible pharmacological bridge between apoB/lipoprotein assembly inhibition and inherited platelet/valvular pathology. The high TxGNN score likely reflects an indirect graph association (e.g., shared lipid-metabolism nodes) rather than a genuine biological signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Taiwan Market Information

Lomitapide is not currently marketed in Taiwan (0 authorizations, 0 licenses on record). No product/dosage form/indication data is available to tabulate.

Safety Considerations

Please refer to the package insert for safety information. (TFDA label warnings/contraindications are flagged as a Blocking data gap — DG001 — and must be obtained before any S1 safety evaluation can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication (macrothrombocytopenia with mitral valve insufficiency) has no clinical trials, no literature, and no plausible mechanistic link — evidence level L5, decision stage S0. There is no basis to advance this candidate.

To proceed, the following is needed:

TFDA label (warnings/contraindications) — currently a Blocking data gap (DG001)
Confirmed mechanism of action and original approved indication(s) for lomitapide — currently missing from the drug record (DG002)
Re-evaluation of ranks 2–8 and 10 in this same prediction set, all of which are likewise L5/Hold with no supporting evidence

⚠️ Data quality note (important for upstream correction): Rank 9 in this same prediction batch, hyperlipoproteinemia, carries strong evidence (12 clinical trials including multiple completed Phase 3 studies, 19 publications) and is the only L1/S3 entry in the set. However, its own rationale flags that this is very likely not a novel repurposing signal — it corresponds to lomitapide's already-approved indication (HoFH, marketed as Juxtapid/Lojuxta, FDA-approved 2012), miscategorized as "new" only because the original_indications field is empty. This should be corrected at the data source before the candidate is scored again, to avoid conflating "confirmed original indication" with "repurposing discovery" in future reports.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.